Both ghrelin and somatostatin (SST) inhibit glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells, but how these independent actions are regulated has been unclear. The mechanism must accommodate noncanonical ghrelin receptor (GHS-R1a)-G-protein coupling to Gα i/o instead of Gα q11 and dependence on energy balance. Here we present evidence for an equilibrium model of receptor heteromerization that fulfills these criteria. We show that GHS-R1a coupling to Gα i/o rather than Gα q11 requires interactions between GHS-R1a and SST receptor subtype 5 (SST5) and that in the absence of SST5 ghrelin enhances GSIS. At concentrations of GHSR1a and SST5 expressed in islets, time-resolved FRET and bioluminescence resonance energy transfer assays illustrate constitutive formation of GHS-R1a:SST5 heteromers in which ghrelin, but not SST, suppresses GSIS and cAMP accumulation. GHS-R1a-G-protein coupling and the formation of GHS-R1a:SST5 heteromers is dependent on the ratio of ghrelin to SST. A high ratio enhances heteromer formation and Gα i/o coupling, whereas a low ratio destabilizes heteromer conformation, restoring GHS-R1a-Gα q11 coupling. The [ghrelin]/[SST] ratio is dependent on energy balance: Ghrelin levels peak during acute fasting, whereas postprandially ghrelin is at a nadir, and islet SST concentrations increase. Hence, under conditions of low energy balance our model predicts that endogenous ghrelin rather than SST establishes inhibitory tone on the β-cell. Collectively, our data are consistent with physiologically relevant GHS-R1a:SST5 heteromerization that explains differential regulation of islet function by ghrelin and SST. These findings reinforce the concept that signaling by the G-protein receptor is dynamic and dependent on protomer interactions and physiological context.
Both ghrelin and somatostatin (SST) inhibit glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells, but how these independent actions are regulated has been unclear. The mechanism must accommodate noncanonical ghrelin receptor (GHS-R1a)-G-protein coupling to Gα i/o instead of Gα q11 and dependence on energy balance. Here we present evidence for an equilibrium model of receptor heteromerization that fulfills these criteria. We show that GHS-R1a coupling to Gα i/o rather than Gα q11 requires interactions between GHS-R1a and SST receptor subtype 5 (SST5) and that in the absence of SST5 ghrelin enhances GSIS. At concentrations of GHSR1a and SST5 expressed in islets, time-resolved FRET and bioluminescence resonance energy transfer assays illustrate constitutive formation of GHS-R1a:SST5 heteromers in which ghrelin, but not SST, suppresses GSIS and cAMP accumulation. GHS-R1a-G-protein coupling and the formation of GHS-R1a:SST5 heteromers is dependent on the ratio of ghrelin to SST. A high ratio enhances heteromer formation and Gα i/o coupling, whereas a low ratio destabilizes heteromer conformation, restoring GHS-R1a-Gα q11 coupling. The [ghrelin]/[SST] ratio is dependent on energy balance: Ghrelin levels peak during acute fasting, whereas postprandially ghrelin is at a nadir, and islet SST concentrations increase. Hence, under conditions of low energy balance our model predicts that endogenous ghrelin rather than SST establishes inhibitory tone on the β-cell. Collectively, our data are consistent with physiologically relevant GHS-R1a:SST5 heteromerization that explains differential regulation of islet function by ghrelin and SST. These findings reinforce the concept that signaling by the G-protein receptor is dynamic and dependent on protomer interactions and physiological context.
GPCR oligomers | glucose homeostasis
T he growth hormone secretagogue receptor type 1a (GHSR1a), was identified in 1996 as an orphan G-protein-coupled receptor (GPCR) that regulates the action of a family of small synthetic molecules designed to rejuvenate the growth hormone (GH) axis in humans (1, 2) . Three years later GHS-R1a was deorphanized by discovery of an endogenous agonist made in the stomach called "ghrelin" (3) . Ghsr −/− mice are refractory to the GH-releasing and orexigenic properties of ghrelin, confirming that GHS-R1a is a physiologically relevant ghrelin receptor (4) . The study we describe was prompted by the need for a model that includes endogenous ghrelin as well as somatostatin (SST) as a regulator of pancreatic islet function and that elucidates the paradox that ghrelin inhibits rather than enhances glucosestimulated insulin secretion (GSIS).
Experiments in ghrelin −/− and ghsr −/− mice led to the conclusion that endogenous ghrelin is a physiologically important regulator of GSIS (5-7). In fed mice endogenous ghrelin concentrations are at a nadir; hence, the majority of GHS-R1a binding sites are unoccupied. In this context, treating WT mice with exogenous ghrelin suppresses GSIS. When WT mice are fasted, endogenous ghrelin levels reach a maximum, and the mice are refractory to exogenous ghrelin. In contrast, fasted ghrelin −/− mice are fully responsive to the suppression of GSIS by exogenous ghrelin. Collectively, these results indicate that in fasted WT mice GHS-R1a binding sites are fully occupied by endogenous ghrelin, suggesting that under conditions of negative energy balance endogenous ghrelin acts by establishing inhibitory tone on insulin secretion.
Endogenous ghrelin is fundamentally important for maintaining euglycemia and for survival under conditions of acute food restriction (7, 8) . Mice lacking the essential enzyme ghrelin octanoylacyltransferase (GOAT), which converts inactive ghrelin peptide into its active octanoylated form, are severely compromised by a 60% reduction in dietary intake (9) (10) (11) . However, the phenotype can be rescued by restoring ghrelin or GH to the concentrations measured in control WT mice subjected to 60% caloric restriction, indicating that ghrelin is critically important for preventing neuroglycopenia (11, 12) . Ironically, expression cloning of GHS-R1a that led to the discovery of ghrelin was achieved using a synthetic molecule that augmented episodic GH release (2, 3) .
GHS-R1a is expressed in pancreatic β-cells, and ghrelin inhibits GSIS (13, 14) . Inhibition of insulin release appears paradoxical, because generally activation of GHS-R1a ghrelin results in coupling to Gαq11, which would enhance insulin secretion. However, in the islet and β-cells, instead ofGα q11 -mediated signal transduction, ghrelin suppresses GSIS via GHS-R1a coupling to Gα i/o , thereby reducing cAMP accumulation (14) . Traditionally; SST activation of somatostatin receptor subtype-5 (SST5) is considered the major inhibitor of insulin secretion from β-cells (15) (16) (17) (18) . SST released from islet δ-cells also inhibits glucagon secretion by activating SST2 on α-cells (19) (20) (21) (22) .
How and under what physiological conditions are the inhibitory actions of ghrelin and SST on insulin secretion independently controlled? Any model that explains ghrelin action on pancreatic β-cells in vivo must include a mechanism for the switch in canonical GHS-R1a-G-protein coupling from Gα q11 to Gα i/o , a role for SST5 and SST, and dependence on reciprocal changes in relative concentrations of ghrelin and SST as a consequence of changes in glucose concentrations. This report provides evidence for a model incorporating GHS-R1a:SST5 heteromers that meet these criteria.
results to develop a system to model ghrelin and SST signaling. Pharmacology studies indicate that SST5 rather than SST2 is primarily involved in inhibiting GSIS from β-cells (15) (16) (17) (18) . We hypothesized that noncanonical GHS-R1a coupling resulting in ghrelin inhibition of GSIS involves molecular interactions between GHS-R1a and SST5. To test the relative contributions of GHS-R1a and SST5, we sought a subclone of INS-1 cells that would allow independent manipulation of GHS-R1a and SST5 to match concentrations present in pancreatic islets. A subclone was identified, INS-1SJ, that expresses SST2, ghrelin, and GOAT at levels similar to those found in rat pancreatic islets with low expression of GHS-R1a and undetectable SST5 (Fig. 1A) .
Increasing GHS-R1a levels alone in INS-1SJ cells by transducing the cells with a GHS-R1a-expressing lentivirus enhanced insulin secretion in either the presence or absence of ghrelin, consistent with GHS-R1a canonical Gα q11 signaling and production of endogenous ghrelin (Fig. 1B) . Because INS1-SJ cells do not express SST5, this result suggested that SST5 is required for ghrelin suppression of GSIS. We then established conditions for expressing GHS-R1a and SST5 at levels closely matching those in pancreatic islets ( Fig. 2A) . INS1-SJ cells expressing GHS-R1a and SST5 (INS1SJ-GHSR-SST5) were treated with ghrelin siRNA to knockdown endogenous ghrelin production (Fig. S1 ). Under these conditions exogenous ghrelin inhibited insulin release induced by 15 mM glucose (Fig. 2B) . When INS1SJ-GHSR-SST5 cells were treated with 3 mM and 15 mM glucose, high glucose increased GSIS, and expression of ghrelin siRNA to knock down production of endogenous ghrelin further enhanced GSIS (Fig. 2C) ; hence, ghrelin siRNA unmasks the suppression of GSIS caused by endogenous ghrelin. Importantly, enhanced GSIS is accompanied by an increase in cAMP (Fig.  2D) , consistent with ghrelin regulation of GSIS reported in pancreatic islets by noncanonical Gα i/o coupling (14) .
Expression of Equivalent Concentrations of GHS-R1a Prevents SST5
Inhibition of GSIS. We next asked if coexpression of equivalent levels of GHS-R1a andSST5 modifies SST5 function. To avoid activating SST2 in INS-1SJ cells, we selected the SST5-selective agonist Bim23052. INS-1SJ cells expressing either SST5 alone or with an equal concentration of GHS-R1a were treated with Bim23052. When SST5 was expressed alone, Bim23052 inhibited GSIS, but coexpression of GHS-R1a blocked Bim23052 action (Fig. 3A) . Native SST5 exists as a monomer, but signal transduction requires agonist-induced formation of homodimers (23); therefore, antagonism of SST5 signaling could be explained by constitutive formation of GHS-R1a:SST5 heteromers. To test this possibility, we used time-resolved (Tr)-FRET SNAP-tag technology (24, 25) , which has the high sensitivity necessary to detect the association of GHS-R1a with SST5 at the concentrations found in pancreatic islets.
In isolation, GHS-R1a exists as homodimers. Previously, we showed by Tr-FRET that dopamine receptor-2 (DRD2) is a competitive inhibitor of GHS-R1a homodimerization, resulting in the formation of GHS-R1a:DRD2 heteromers (26) . Using similar methods employing SNAP-GHS-R1a, Tr-FRET illustrates the formation of GHS-R1a:GHS-R1a homodimers on the plasma membrane of INS-1SJ cells (Fig. 3B ). Concentration-dependent inhibition of the Tr-FRET signal is observed when SST5 is coexpressed with SNAP-GHS-R1a at ratios of 1/1 and 2/1 (Fig. 3B) . Control experiments confirmed that attenuation of the Tr-FRET signal was not a consequence of coexpressed SST5 inhibiting transport of SNAP-GHS-R1a to the plasma membrane (Fig. S2) ; therefore, the marked inhibition of GHS-R1a homodimerization by SST5 is a consequence of high-affinity interactions between GHS-R1a and SST5.
SST5-Dependent Modification of GHS-R1a-G-protein Coupling Is
Controlled by the [Ghrelin]/[SST] Ratio. Both ghrelin and SST are capable of inhibiting insulin secretion by a mechanism requiring Gα i/o suppression of cAMP accumulation. Above we showed that ghrelin inhibition of GSIS and suppression of cAMP accumulation, as well as GHS-R1a-dependent antagonism of inhibition of GSIS by a selective SST5 agonist, are dependent on both GHSR1a and SST5. To elucidate the mechanism more completely and to deduce the relative contributions of SST2 and SST5, a cell system was needed in which the relative concentrations of ghrelin, SST, GHS-R1a, SST5, and SST2 could be controlled. Precise control requires a null background; therefore, we selected HEK293 cells. Because inhibition of GSIS by ghrelin and SST in pancreatic β-cells and in the INS-1SJ β-cell line is dependent on the inhibition of cAMP production, we selected cAMP accumulation as a surrogate for GSIS. We next tested whether interactions between GHS-R1a and SST5 affected SST suppression of cAMP accumulation. In HEK293 cells expressing SST5, SST dose-dependently suppresses forskolin-induced cAMP accumulation with maximum inhibition at 1-10 nM (Fig. S3A) . Remarkably, as in the INS-1SJ cells, coexpressing GHS-R1a with SST5 made the cells refractory to SST (Fig. S3B) ; however, treatment with ghrelin, but not with desacyl ghrelin (Fig. S3C) , inhibits forskolin-induced cAMP accumulation by a pertussis toxin (PTX)-sensitive mechanism (Fig.  S3D) . Hence, the noncanonical GHS-R1a-G-protein coupling to Gα i/o observed in pancreatic β-cells and INS-1SJ β-cells is recapitulated in HEK293 cells coexpressing GHS-R1a and SST5.
Tr-FRET analysis in INS-1SJ cells used fluorophor tagging at the GHS-R1a N terminus. As an additional test of heteromer formation, we used bioluminescence resonance energy transfer (BRET) with GHS-R1a and SST5 tagged at the C terminus with In each case, data represent means ± SEM (n = 4); *P < 0.05, **P < 0.01, ***P < 0.001. either the energy donor luciferase or GFP as acceptor (27) . A fixed DNA concentration of donor and increasing concentrations of acceptor at ratios of 1/1-1/18 were transfected into HEK293 cells, and the BRET ratio was plotted as a function of the relative concentrations of donor and acceptor. The hyperbolic function obtained with the GHS-R1a-Rluc and SST5-GFP pair and the BRET 50 ratio indicates high-affinity interactions (upper curve in Fig. 4A ; BRET 50 ∼2). An identical result is obtained when donorand acceptor-tagged receptors are reversed (SST5-Rluc and GHSR1a-GFP). In contrast, titration of SST5-Rluc + SST5-GFP (lower curve in Fig. 4A ) and GHS-R1a-Rluc + SST2-GFP (Fig.  4B) produces linear BRET functions indicating random collisions rather than heteromer formation. We next asked whether heteromer formation correlated with resistance to SST inhibition of cAMP accumulation. Cells coexpressing GHS-R1a with either SST5 or SST2 were treated with forskolin and SST. With SST5 coexpression, SST did not inhibit cAMP accumulation (Fig. 4C) , whereas with SST2 coexpression SST inhibited forskolin-induced cAMP accumulation (Fig. 4D) . Hence, as observed in INS1SJ-GHSR-SST5 cells, formation of GHS-R1a:SST5 heteromers blocks SST responsiveness in favor of ghrelin responsiveness. (Fig. 5A ). To test if SST antagonism of ghrelin inhibition of cAMP accumulation is accompanied by restoration of canonical GHS-R1a-Gα q11 coupling, HEK293 cells expressing GHS-R1a, SST5, and aequorin were used (1, 28) . Consistent with an equilibrium between GHS-R1a coupling to Gα i/o and Gα q11 , lowering the [ghrelin]/[SST] ratio produces a dose-dependent increase in the internal calcium concentration ([Ca 2+ ] i ) mobilization as measured by aequorin bioluminescence (Fig. 5B) . Next we performed BRET assays in the absence or presence of ghrelin with increasing SST concentrations to test whether the specificity of GHS-R1a-G-protein coupling correlates with heteromer formation. Ghrelin markedly increased the BRET ratio which was dose-dependently attenuated by SST (Fig. 5C ). These results are consistent with agonist concentration-dependent equilibrium between GHSR1a:SST5 and GHS-R1a:GHS-R1a dimers, which in turn regulate noncanonical and canonical GHS-R1a signal transduction, respectively.
Discussion
Based on our results, we propose a model of regulation of pancreatic islet function incorporating endogenous ghrelin and SST. Although GHS-R1a normally couples to Gα q11 , both ghrelin and SST inhibit GSIS secretion via GHS-R1a and SST5 coupling to Gα i/o . To test conclusively for GHS-R1a and SST5 molecular interactions and to deduce how combinations of ghrelin and SST might regulate signal transduction differentially, we identified a clone of INS-1 cells (INS-1SJ) that formed a basis for our studies. By matching concentrations of GHS-R1a and SST5 in INS-1SJ cells to those expressed in pancreatic islets, we conclude that, contrary to current belief, ghrelin rather than SST suppresses GSIS and cAMP accumulation through a PTX-sensitive mechanism. This outcome is surprising, because canonical ghrelin signaling through GHS-R1a (via Gα q11 ) would mobilize [Ca 2+ ] i and stimulate rather than inhibit insulin secretion. Indeed, transducing INS-1SJ cells with lentivirus encoding GHS-R1a enhanced insulin secretion. However, when GHS-R1a is coexpressed with SST5 in INS-1SJ cells at concentrations and relative ratios commensurate with those measured in native rat islets, ghrelin inhibits insulin secretion, supporting our hypothesis of physiologically relevant molecular interactions between GHS-R1a and SST5.
To determine the mechanism by which ghrelin inhibits insulin secretion via noncanonical GHS-R1a-G-protein coupling, we tested for GHS-R1a:SST5 heteromer formation using highly sensitive Tr-FRET and BRET assays. Tr-FRET used receptors tagged at the N terminus, and for BRET receptors were tagged at the C terminus. Each method used relative and absolute expression levels of GHS-R1a and SST5 closely matching those in rat pancreatic islets. The results of the two different experimental methods are in complete agreement and illustrate high-affinity interactions between GHS-R1a and SST5 at equimolar concentrations. Indeed, these results support our hypothesis that the atypical GHSR1a-G-protein coupling essential for ghrelin suppression of GSIS is a consequence of the formation of GHS-R1a:SST5 heteromers. Most importantly, we show that differential GHS-R1a-G-protein coupling and signal transduction are influenced by the relative concentrations of ghrelin and SST. In cells coexpressing GHSR1a and SST5, when the relative [ghrelin]/[SST] ratio is high, ghrelin suppresses cAMP accumulation; when the ratio is low, the cells are refractory to ghrelin inhibition of cAMP production, and ghrelin increases [Ca 2+ ] i mobilization, consistent with restoration of GHS-R1a-Gα q11 coupling. Furthermore, reducing the [ghrelin]/[SST] ratio lowers the BRET ratio, consistent with dissociation of GHS-R1a:SST5 heteromers, thereby implicating an agonist concentration-dependent equilibrium model of heteromerization. Of course, we cannot preclude the possibility that changes in the BRET ratio also might be explained by a change in conformation of the GHS-R1a:SST5 heteromer resulting in altered G-protein coupling.
Constitutive formation of GHS-R1a:SST5 heteromers explains why GHS-R1a antagonizes SST5 suppression of GSIS and cAMP accumulation. Because SST-induced formation of SST5:SST5 homomers is required for signal transduction (23) , the insensitivity to SST argues that formation of SST5:SST5 or GHS-R1a:GHSR1a homomers is energetically unfavorable compared with GHSR1a:SST5 formation. Indeed, we speculate that the heteromer acts as a buffer preventing ghrelin-induced insulin secretion by GHS-R1a-Gα q coupling and oversuppression of insulin release by unopposed SST5 coupling to Gα i/o .
We propose a model that defines a role for ghrelin and GHSR1a for controlling glucose homeostasis according to energy balance (Scheme 1). We show that when GHS-R1a and SST5 are coexpressed, they are functionally and physically associated, resulting in coupling to Gα i/o . The physical association of GHSR1a and SST5 allows signal transduction to be regulated tightly according to the relative concentrations of ghrelin and SST. Under conditions of low energy balance, ghrelin concentrations are elevated, resulting in GHS-R1a:SST5-mediated inhibition of insulin secretion. Ghrelin also stimulates glucagon secretion by direct effects on α-cells and indirectly by disinhibiting insulin suppression of α-cell activity (29) (30) (31) . As well as inhibiting GSIS, ghrelin inhibits arginine-induced SST secretion (32) . In the context of positive energy balance, high glucose lowers circulating ghrelin (14, 33) , thereby relieving the ghrelin suppression of insulin release from β-cells and stimulating the release of SST from δ-cells (34) ; SST, in turn, activates SST2 on α-cells, suppressing glucagon secretion (34) . Therefore, only in states of low energy balance does ghrelin play a dominant role in regulating glucose homeostasis.
Recent studies show that glucose inhibits glucagon secretion in WT mice but not in sst −/− mice, as is consistent with a direct role for glucose on SST secretion (33) . The rapid cessation of insulin release upon glucose removal is the same in WT and sst −/− mouse islets, indicating that termination of the insulin-secretory response is not regulated by SST from δ-cells. This result is consistent with our model, which proposes that when glucose levels fall in vivo, it is ghrelin rather than SST that establishes an inhibitory set point on the β-cell to control insulin secretion (Scheme 1). This effect is not observed in isolated mouse islets after glucose removal because, unlike rat and human islets, mouse islets do not produce ghrelin.
In summary, we provide evidence for an equilibrium model in which the formation of GHS-R1a:SST5 heteromers is controlled by the [ghrelin]/[SST] ratio; hence, ghrelin and SST differentially establish a set point for β-cell insulin secretion. Of course, implicit in our equilibrium model is dependence on the relative concentrations of GHS-R1a and SST5. In rat islets, we show both are expressed at approximately equal concentrations. Clearly the results obtained from model systems do not necessarily equate to primary β-cells; nevertheless, the proposed mechanism is conceptually consistent with observations made in isolated islets. Finally, our results reinforce the notion that regulation of intracellular signaling by GPCRs is not simply a linear relationship but is dependent on modulation via receptor signaling networks that can be modified according to relative agonist concentrations and relative GPCR concentrations.
Experimental Procedures
Expression Constructs. GHS-R1a-GFP was constructed as described previously (27) . The GHS-R1a-Rluc:human GHS-R1a cDNA fragment was inserted inframe into the EcoRI/EcoRV sites of the pRluc-N1 vector (Perkin Elmer). Human SST5 and SST2 cDNA constructs were purchased from Missouri S&T cDNA Resource Center (www.cdna.org). The SST5-GFP:SST5 cDNA fragment was inserted in-frame into the EcoRI/EcoRV sites of the pGFP-N3 vector β β-cell α -cell δ -cell (Perkin Elmer). The SST5-Rluc:SST5 cDNA fragment was inserted in-frame into the EcoRI/EcoRV sites of the pRluc-N1vector (Perkin Elmer). The integrity of all tagged GHS-R1a, SST5, and SST2 expression constructs was confirmed by nucleotide sequencing and tested to check that they displayed functional characteristics identical to those of WT receptors in transfected cells. SNAP-GHS-R1a was prepared as described previously (26) .
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INS-1SJ Cell Line and GSIS. INS-1 832/13 cells that exhibit robust GSIS derived from a rat insulinoma were a kind gift from Chris Newgard (Duke University Medical Center, Winston Salem, NC). A subclone of these cells, which we named "INS-1SJ," was selected specifically for our experiments because it allowed testing of the hypothesis that ghrelin attenuation of GSIS is dependent on GHS-R1a and SST5 by independently matching expression levels of GHS-R1a and SST5 to match levels in rat pancreatic islets. Eighteen hours before GSIS experiments, the standard tissue culture medium for INS-1 cells containing 11.1 mM glucose was changed to fresh medium containing 5 mM glucose (35) . Insulin secretion was assayed in HBSS (114 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 116 mM MgSO 4 , 20 mM Hepes, 2.5 mM CaCl2, 25.5 mM NaHCO3, and 0.2% BSA, pH 7.2). At confluence, cells were washed with 1 mL HBSS containing 3 mM glucose followed by a 2-h preincubation in 2 mL of the same buffer. Then insulin secretion was measured after static incubation or 2 h in 0.8 mL of HBSS containing the glucose concentrations and/or ghrelin, SST, or Bim23052 as indicated in the figures. Insulin was measured using the rat/mouse insulin ELISA kit (Linco Research). Acid alcohol was added to extract total protein, which was assayed using the Coomassie protein assay reagent kit (Pierce Biotechnology). Secreted insulin was normalized to total protein.
Measurements of Intracellular cAMP. cAMP was measured in INS-1SJ cells using the cAMP dynamic 2 kit (Cisbio) using homogeneous time-resolved fluorescence technology. cAMP levels were calculated by fluorescence ratio (665 nm/ 620 nm). Forty-eight hours after transfection, the transfected HEK293 cells were detached using nonenzymatic cell dissociation solution (Sigma), were washed with HBSS, and were resuspended in stimulation buffer [1× PBS with 0.04% BSA (pH 7.4) and 0.5 mmol/L 3-isobutyl-1-methylxanthine]. cAMP accumulation also was determined using the Lance cAMP 384 kit from Perkin Elmer.
Live-Cell Tr-FRET and BRET. Cells were labeled 48 h after being transfected by electroporation as described previously (26) . Briefly, SNAP-GHS-R1a-transfected cells were incubated in the presence of 25 nM of donor benzyl guanineconjugated terbium cryptate (BG-TbK) (SNAP-Lumi4-Tb; Cisbio) and 250 nM of acceptor benzyl guanine-conjugated d2 fluorophore (BC-647) (SNAP-surface 647; New England BioLabs) for 1 h at 37°C in 0.5% FBS containing RPMI medium. Tr-FRET signals were measured at 665 nm and 620 nm after excitation at 337 nm with 50-μs delay and integration time of 400 μs by using an EnVision plate reader (Perkin Elmer). The ratio of fluorescence (665 nm/620 nm) was calculated for each sample. BRET experiments were based on previous studies (27) . Details are given in SI Experimental Procedures.
Aequorin Bioluminescence Assay. The aequorin bioluminescence assay was carried out as described in ref. 28 . Human ghrelin and SST (Phoenix) were diluted with modified HBSS (25 mM Hepes at pH 7.3) and distributed into 96-well plates. Assays were performed with the Luminoskan Luminometer (ThermoFisher Labsystems). The fractional luminescence for each well was calculated by taking the ratio of the integrated response to the initial challenge to the total integrated luminescence, as well as the Triton X-100 lysis response. Fractional luminescence data for each point represent the average of triplicate measurements. Statistical analyses were performed using the Student t test.
Additional methods are described in SI Experimental Procedures.
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